Zytiga issue shows urgent need for more flexible NHS pricing models, ICR says

15 July 2021

The Institute of Cancer Research (ICR) has hit out at a decision by the National Institute for Health and Care Excellence (NICE) not to recommend Zytiga (abiraterone) as a first-line National Health Service (NHS) treatment for newly-diagnosed, advanced prostate cancer.

The NICE first rejected the Johnson & Johnson (NYSE: NJ) subsidiary Janssen drug in this indication in June 2020. Then, four months later, the cost-effectiveness watchdog announced it would reconsider its decision.

"We continue to urge NICE and the drug’s manufacturer to sit down together"But now, NICE has concluded not to recommend Zytiga once again. This means men in England and Wales who are first diagnosed with advanced prostate cancer have three options.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK